Doctors inject chemo directly into lung tumors in early trial

NCT ID NCT04311762

Ongoing Disease control Sponsor: University of Vermont Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new method to deliver the chemotherapy drug cisplatin directly into lung tumors using a bronchoscope. The goal is to find the safest dose and see if this approach can help control stage IV lung cancer. Only 16 participants are enrolled, and the main focus is on safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cisplatin
What this could lead to: If successful, this could provide a new way to deliver chemotherapy directly to lung tumors, potentially reducing side effects and improving local control.
What could go wrong: This is a very early phase 1 trial with only 16 participants, focused on safety and dosing. It may not show significant benefit, and there are risks from the procedure and drug toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer metastatic malignant neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER METASTATIC

Contacts and locations

Locations

University of Vermont

Burlington, Vermont, 05405, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.